Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Arrowhead Research (ARWR) to Eliminate Chief Scientific Officer Position
December 1, 2016 4:58 PM ESTArrowhead Research (NASDAQ: ARWR) notified David Lewis, the Companys Chief Scientific Officer, that his position will be terminated, effective December 13, 2016.
This follows recent news that the company will be discontinuing development of its clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which... More
William Blair Downgrades Arrowhead Research (ARWR) to Market Perform
November 30, 2016 8:23 AM ESTWilliam Blair downgraded Arrowhead Research (NASDAQ: ARWR) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.
Shares of Arrowhead Research closed at $4.39 yesterday.
... MoreArrowhead Research (ARWR) PT Slashed to $2 at Jefferies
November 30, 2016 8:12 AM ESTJefferies analyst Eun Yang lowered his price target on Arrowhead Research (NASDAQ: ARWR) to $2.00 (from $5.00) while maintaining a Hold rating after the company discontinues its EX1-based clinical programs (ARC-520, ARC-521, ARC-AAT) given likely "substantial" delays due to need for add'l non-clinical studies due... More
Cantor Fitzgerald Downgrades Arrowhead Research (ARWR) to Hold
November 30, 2016 6:58 AM ESTCantor Fitzgerald downgraded Arrowhead Research (NASDAQ: ARWR) from Buy to Hold with a price target of $1.00 (from $15.00).
For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.
Shares of Arrowhead Research closed at $4.39 yesterday.
... MorePiper Jaffray Downgrades Arrowhead Research (ARWR) to Neutral
November 30, 2016 6:57 AM ESTPiper Jaffray downgraded Arrowhead Research (NASDAQ: ARWR) from Overweight to Neutral with a price target of $2.00 (from $10.00).
For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.
Shares of Arrowhead Research closed at $4.39 yesterday.
... MoreChardan Capital Markets Downgrades Arrowhead Research (ARWR) to Neutral on EX-1 RNAi Program Discontinuations
November 30, 2016 6:19 AM ESTChardan Capital Markets downgraded Arrowhead Research (NASDAQ: ARWR) from Buy to Neutral with a price target of $2.00 (from $8.00) on EX-1 RNAi program discontinuations.
Analyst Madhu Kumar commented, "As previously highlighted, the Bear Case for ARWR has occurred, with broad loss of the EX-1 based clinical pipeline. In our 10 November 2016 company note, we highlighted both bullish and bearish scenarios for... More
Arrowhead Research (ARWR) sinks 69% as trading resumes
November 29, 2016 4:31 PM ESTArrowhead Research (NASDAQ: ARWR) sinks 69% as trading resumes.
... More